Novo Nordisk has signed a deal worth around $3.3 billion to acquire Dicerna Pharmaceuticals, a US-based biotech company focused on developing ribonucleic acid interference (RNAi) therapies. Based in Lexington, Massachusetts, Dicerna Pharmaceuticals leverages its proprietary GalXC and GalXC-Plus RNAi technologies to develop therapies to preferentially silence genes that either cause or contribute to disease. The […]
Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are joining forces to develop and commercialize ribonucleicacid interference therapies (RNAi therapeutics) for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (alpha-1 liver disease). As part of the alliance, Alnylam Pharmaceuticals’ ALN-AAT02 and Dicerna Pharmaceuticals’ DCR-A1AT, both investigational RNAi therapeutics will be evaluated in alpha-1 liver disease. Both the RNAi […]
Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B virus (HBV) infection using its GalXC RNAi platform technology. The collaboration between the Dicerna Pharmaceuticals and the Swiss drugmaker will focus on the global development and commercialization of the former’s […]